An Open, Single-center, Phase II Clinical Study of Hetrombopag in Secondary Prevention of XPO-1 Inhibitor Selinexor Combined With Chemotherapy Induced Thrombocytopenia in Lymphoma
To explore the efficacy and safety of hetrombopag for secondary prevention of thrombocytopenia caused by XPO-1 inhibitor Selinexor combined with chemotherapy in patients with lymphoma.
NCT05969158 — Chemotherapy-Induced Thrombocytopenia
Status: Not yet recruiting
http://inclinicaltrials.com/chemotherapy-induced-thrombocytopenia/NCT05969158/
The Role of Sonoelastography in Evaluation of Therapeutic Response in Patients With Lymphoma.
To determine accuracy of elastography in assessment of superficial lymph nodes response to treatment in cases of lymphoma.
NCT05967975 — Lymphoma
Status: Not yet recruiting
http://inclinicaltrials.com/lymphoma/NCT05967975/
Phase 1, Open-Label Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by Intratumoral Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
NCT05967416 — Refractory Non-Hodgkin Lymphoma
Status: Recruiting
http://inclinicaltrials.com/refractory-non-hodgkin-lymphoma/NCT05967416/
An Open-Label, Multicenter, Phase I Study of AXT-1003 as a Single Agent in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.
NCT05965505 — Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Recruiting
http://inclinicaltrials.com/relapsed-or-refractory-non-hodgkin-s-lymphoma/NCT05965505/
Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
This is a Phase 1/1b, open-label, dose-escalation study to evaluate the safety and the efficacy of anti-CD19 chimeric antigen receptor (CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
NCT05963217 — Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Recruiting
http://inclinicaltrials.com/relapsed-or-refractory-chronic-lymphocytic-leukemia/NCT05963217/
Chidamide Plus Azacitidine Epigenetic Repression for the Treatment of Previously Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
Untreated patients with Nodal T-follicular Helper (TFH) Cell Lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim evaluation of CR, consolidation therapy with ASCT or another eight cycles with chidamide combined with azacitidine can be obtained. For patients with interim evaluation of PR, another two cycles of chidamide combined with azacitidine will be continued, followed by the second efficacy evaluation, and those who achieve CR receive consolidation therapy with ASCT or another six cycles of chidamide combined with azacitidine. Subsequently, chidamide was given as maintenance therapy for 12 months. Patients with SD or PD withdrew from this study.
NCT05958719 — Peripheral T Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/peripheral-t-cell-lymphoma/NCT05958719/
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL: Multicenter Retrospective Study (Real World Evidence - RWE)
National, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma, clinical management, treatment in molecular subgroups, progression profile and patient survival outcomes enrolled and treated within the last 6 years (2017 to 2022), in national cancer reference centers.
NCT05958134 — Diffuse Large B Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/diffuse-large-b-cell-lymphoma/NCT05958134/
A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
NCT05956041 — Cutaneous T Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/cutaneous-t-cell-lymphoma/NCT05956041/
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib
NCT05951959 — Mantle Cell Lymphoma (MCL)
Status: Recruiting
http://inclinicaltrials.com/mantle-cell-lymphoma-mcl/NCT05951959/
Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma
This study intends to apply for the establishment of research beds, establish a Chinese PVRL research cohort, and carry out a to achieve the following research objectives: The goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma（PVRL）. The study is to achieve the following research objectives: 1. To establish a comprehensive diagnostic criteria for PVRL with high diagnostic efficiency and strengthen the PVRL diagnostic system; 2. To establish a standardized treatment pathway for PVRL and evaluate the efficacy and safety of treatment; 3. To screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of PVRL； 4. To explore the pathogenesis of PVRL, specific tumor markers and drug therapeutic targets.
NCT05950490 — Primary Vitreoretinal Lymphoma
Status: Recruiting
http://inclinicaltrials.com/primary-vitreoretinal-lymphoma/NCT05950490/